With purpose-built functionalities for the design and evaluation of large panels of cell-based therapeutic modalities for novel immunotherapies, such as chimeric antigen receptors T cells (CAR-T), T Cell Receptor Technology (TCRs), and antibody TCR-mimetics, Genedata Biologics® enables the systematic engineering, production, and testing of novel therapeutic modalities.
CAR-Ts. TCR-Ts. NKs. TILs.
Genedata Biologics streamlines the full process from design, generation, testing, and validation, to developability and manufacturability assessments. By directly integrating with laboratory equipment, it fully automates sample handling and testing procedures. An integrated database and tools support screening and engineering of a variety of TCR-based formats (e.g., dsTCR, TCR-scFv, bispecific TCRs).
Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow.
Dominik Maurer, Ph.D.
VP Immunology
Given their track-record of success, Genedata’s platform was the clear choice to support and integrate our full cell therapy discovery and development efforts.
Marc Van Dijk, Ph.D.
Chief Technology Officer
Immatics streamlines CGT processes with Genedata
"The Genedata platform has provided efficiency gains on many fronts, eliminated redundancies in our daily work, and decreased our overall ongoing operating costs." Sebastian Bunk, Ph.D., Senior Director TCR Bispecifics Pipeline, Immatics.
Helping MorphoSys Increase Efficiencies Across Their R&D
"Given their track-record of success, Genedata’s platform was the clear choice to support and integrate our full cell therapy discovery and development efforts.” Marc Van Dijk, Ph.D., Chief Technology Officer